uniQure publishes presentation on AMT-260 gene therapy delivery for epilepsy
QURE•uniQure published a presentation on its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy. As of May 29, 2026, four of six participants had Grade 1 or Grade 2 adverse events, and mean hippocampal coverage was 42% in the head and 33% in the body.




